Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2

5(62.5%)

Phase 1

2(25.0%)

N/A

1(12.5%)

8Total

Phase 2(5)

Phase 1(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT04777175Recruiting

A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer

Role: lead

NCT04144569Phase 2Recruiting

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

Role: lead

NCT04144608Phase 2Completed

Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC

Role: lead

NCT06521034Phase 1Completed

First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer

Role: lead

NCT03807102Phase 1Unknown

Trial of Tumor Vaccine Used for Adjuvant Therapy in Post Radical Operation Patients With Lung Cancer

Role: lead

NCT03646968Phase 2Unknown

Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study

Role: lead

NCT05530785Not ApplicableUnknown

Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT

Role: lead

NCT04144582Phase 2Completed

Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer

Role: lead

NCT03652857Phase 2Completed

Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer

Role: lead

NCT03780439Completed

Procalcitonin to Predict Infection After Gastrectomy for Gastric Cancer

Role: lead

All 10 trials loaded